United States: FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar - Goodwin Procter LLP

On April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and Johnson's STELERA® (ustekinumab).